The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Open accessAbstract
More than 1.6 million new cases of cancer will be diagnosed in the U.S. in 2016, resulting in more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in advanced cancers, immunotherapy development, particularly with PD-1 inhibitors, has changed the face of treatment for a number of tumor types. One example is the subset of tumors characterized by mismatch repair deficiency and microsatellite instability that are highly sensitive to PD-1 blockade. Hereditary forms of cancer have been noted for more than a century, but the molecular changes underlying mismatch repair-deficient tumors and subsequent microsatellite unstable tumors was not known until the early 1990s. In this review article, we discuss the history and pathophysiology of mismatch repair, the process of testing for mismatch repair deficiency and microsatellite instability, and the role of immunotherapy in this subset of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Risk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev, Y., Pal, T., Rosen, B. P., McLaughlin, J. R., Sellers, T. A., Risch, H. A., Zhang, S., Ping, S., Narod, S. A., & Schildkraut, J. M. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31829a5527 · Cited by 18
RetractedRisk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev, Y., Pal, T., Rosen, B. P., McLaughlin, J. R., Sellers, T. A., Risch, H. A., Zhang, S., Sun, P., Narod, S. A., & Schildkraut, J. M. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000134 · Cited by 11
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Cited by
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer
Jiang, Y., Zhang, Q., Hu, Y., Li, T., Yu, J., Zhao, L., Ye, G., Deng, H., Mou, T., Cai, S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002116 · Cited by 458
Jiang, Y., Xie, J., Han, Z., Liu, W., Xi, S., Huang, L., Huang, W., Lin, T., Zhao, L., Hu, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0848 · Cited by 143
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
Davies, H., Morganella, S., Purdie, C. A., Jang, S. J., Borgen, E., Russnes, H., Glodzik, D., Zou, X., Viari, A., Richardson, A. L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1083 · Cited by 99
Metadata
- Authors
- Lee, V., Murphy, A., Le, D. T., & Diaz, L. A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-07-13
- Volume
- 21
- Issue
- 10
- Pages
- 1200-1211
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2467321712
- Cited by
- 283
- References
- 162
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. https://app.cochat.ai/papers/10.1634/theoncologist.2016-0046
- The paper
- Lee, V., Murphy, A., Le, D. T., & Diaz, L. A. (2016). Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. The Oncologist. https://doi.org/10.1634/theoncologist.2016-0046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
